Fanny Foubert1, Maëva Salimon1, Clotilde Dumars2, Nicolas Regenet3, Paul Girot1, Aurélien Venara4,5, Hélène Senellart6, Marie-Françoise Heymann7, Tamara Matysiak-Budnik1,5, Yann Touchefeu1,5. 1. IMAD, Department of Gastroenterology & Digestive Oncology, Nantes University Hospital, Nantes, France. 2. Department of Pathology, Nantes University Hospital, Nantes, France. 3. IMAD, Department of Digestive Surgery, Nantes University Hospital, Nantes, France. 4. Department of Digestive Surgery, Angers University Hospital, Angers, France. 5. INSERM U1235, Nantes University, Nantes, France. 6. Department of Medical Oncology, Cancer Research Institute, Saint Herblain, France. 7. Department of Pathology, Cancer Research Institute, Saint Herblain, France.
Abstract
BACKGROUND: Intestinal and pancreatic neuroendocrine tumors (IP-NETs) are rare tumors with heterogeneous outcomes. The aim of our study was to determine the clinical, therapeutic and pathological factors which impact the overall survival (OS) in IP-NETs. METHODS: All the patients diagnosed with IP-NETs at the Nantes University Hospital between October 1994 and October 2013 were retrospectively analysed. Patients with MEN-1 (Type 1 Multiple Endocrine Neoplasia) or Von Hippel-Lindau syndrome were excluded. Additionally, a prospective analysis of tumor grade (mitotic index and Ki67 index) was performed on tumor samples. OS was evaluated by Kaplan-Meier method and prognostic factors by log-rank test and Cox model. RESULTS: The study included 151 patients. Median age was 60 (range, 14-81). Primary tumor was pancreatic in 86 patients (56.95%) and intestinal in 65 patients (43.05%). Tumors were metastatic (synchronous or metachronous) in 72 patients (47.7%). The median OS was 157 months. For all IP-NETs, age >65 years (P<0.0001), Ki67 >5% (P=0.03), synchronous metastases (P=0.016), primary tumor size >25 mm (P=0.03) and emergency surgery (P=0.007) were independent poor prognostic factors. CONCLUSIONS: In this large series of patients with IP-NET, age >65 years, Ki67 >5%, primary tumor size >25 mm, synchronous metastases and emergency surgery for acute complications have been identified as independent poor prognostic factors.
BACKGROUND: Intestinal and pancreatic neuroendocrine tumors (IP-NETs) are rare tumors with heterogeneous outcomes. The aim of our study was to determine the clinical, therapeutic and pathological factors which impact the overall survival (OS) in IP-NETs. METHODS: All the patients diagnosed with IP-NETs at the Nantes University Hospital between October 1994 and October 2013 were retrospectively analysed. Patients with MEN-1 (Type 1 Multiple Endocrine Neoplasia) or Von Hippel-Lindau syndrome were excluded. Additionally, a prospective analysis of tumor grade (mitotic index and Ki67 index) was performed on tumor samples. OS was evaluated by Kaplan-Meier method and prognostic factors by log-rank test and Cox model. RESULTS: The study included 151 patients. Median age was 60 (range, 14-81). Primary tumor was pancreatic in 86 patients (56.95%) and intestinal in 65 patients (43.05%). Tumors were metastatic (synchronous or metachronous) in 72 patients (47.7%). The median OS was 157 months. For all IP-NETs, age >65 years (P<0.0001), Ki67 >5% (P=0.03), synchronous metastases (P=0.016), primary tumor size >25 mm (P=0.03) and emergency surgery (P=0.007) were independent poor prognostic factors. CONCLUSIONS: In this large series of patients with IP-NET, age >65 years, Ki67 >5%, primary tumor size >25 mm, synchronous metastases and emergency surgery for acute complications have been identified as independent poor prognostic factors.
Authors: Ben Lawrence; Bjorn I Gustafsson; Anthony Chan; Bernhard Svejda; Mark Kidd; Irvin M Modlin Journal: Endocrinol Metab Clin North Am Date: 2011-03 Impact factor: 4.741
Authors: Skye C Mayo; Mechteld C de Jong; Carlo Pulitano; Brian M Clary; Srinevas K Reddy; T Clark Gamblin; Scott A Celinksi; David A Kooby; Charles A Staley; Jayme B Stokes; Carrie K Chu; Alessandro Ferrero; Richard D Schulick; Michael A Choti; Giles Mentha; Jennifer Strub; Todd W Bauer; Reid B Adams; Luca Aldrighetti; Lorenzo Capussotti; Timothy M Pawlik Journal: Ann Surg Oncol Date: 2010-06-29 Impact factor: 5.344
Authors: John G Touzios; James M Kiely; Susan C Pitt; William S Rilling; Edward J Quebbeman; Stuart D Wilson; Henry A Pitt Journal: Ann Surg Date: 2005-05 Impact factor: 12.969
Authors: James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans Journal: J Clin Oncol Date: 2008-06-20 Impact factor: 44.544
Authors: A Ahmed; G Turner; B King; L Jones; D Culliford; D McCance; J Ardill; B T Johnston; G Poston; M Rees; M Buxton-Thomas; M Caplin; J K Ramage Journal: Endocr Relat Cancer Date: 2009-05-20 Impact factor: 5.678